MIGDEN, M.; SCHMULTS, C.; KHUSHALANI, N.; GUMINSKI, A. .; CHANG, A. L.; LEWIS, K. .; ANSSTAS, G. .; BOWYER, S. .; HUGHES, B. .; SCHADENDORF, D. .; MODI, B. .; DUNN, L. .; FLATZ, L. .; HAUSCHILD, A. .; YOO, S.-Y. .; BOOTH, J. .; SEEBACH, F. .; LOWY, I. .; FURY, M. .; RISCHIN, D. . Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 Groups 1, 2, and 3. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 2, p. s176, 2023. DOI: 10.25251/skin.7.supp.176. Disponível em: https://jofskin.org/33014/index.php/skin/article/view/2001. Acesso em: 4 jul. 2024.